179 related articles for article (PubMed ID: 26149475)
1. Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival.
Jin Y; Sun PL; Park SY; Kim H; Park E; Kim G; Cho S; Kim K; Lee CT; Chung JH
Lung Cancer; 2015 Sep; 89(3):343-9. PubMed ID: 26149475
[TBL] [Abstract][Full Text] [Related]
2. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
Go H; Kim DW; Kim D; Keam B; Kim TM; Lee SH; Heo DS; Bang YJ; Chung DH
J Thorac Oncol; 2013 Nov; 8(11):1445-50. PubMed ID: 24128715
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
Park E; Choi YL; Ahn MJ; Han J
Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
[TBL] [Abstract][Full Text] [Related]
5. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
6. Rare Incidence of
Lim SM; Yoo JE; Lim KH; Meng Tai DW; Cho BC; Park YN
Cancer Res Treat; 2017 Jan; 49(1):185-192. PubMed ID: 27121721
[TBL] [Abstract][Full Text] [Related]
7. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
8. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
[TBL] [Abstract][Full Text] [Related]
10. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
11. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
12. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
13. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
[TBL] [Abstract][Full Text] [Related]
15. ROS1 copy number alterations are frequent in non-small cell lung cancer.
Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
[TBL] [Abstract][Full Text] [Related]
16. A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.
Zhao J; Chen X; Zheng J; Kong M; Wang B; Ding W
Histopathology; 2018 Jul; 73(1):19-28. PubMed ID: 29464758
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
Luk PP; Selinger CI; Mahar A; Cooper WA
Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
[TBL] [Abstract][Full Text] [Related]
18. ROS1 gene rearrangement and copy number gain in non-small cell lung cancer.
Jin Y; Sun PL; Kim H; Park E; Shim HS; Jheon S; Kim K; Lee CT; Chung JH
Virchows Arch; 2015 Jan; 466(1):45-52. PubMed ID: 25374304
[TBL] [Abstract][Full Text] [Related]
19. The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.
Fu S; Liang Y; Lin YB; Wang F; Huang MY; Zhang ZC; Wang J; Cen WJ; Shao JY
PLoS One; 2015; 10(4):e0124354. PubMed ID: 25905642
[TBL] [Abstract][Full Text] [Related]
20. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]